
XERS P/E Ratio
P/E Ratio as of Jul 2, 2025: -15.68
Average-15.13
Median-15.19
Minimum-15.72
Maximum-14.42
-15.68
Past Month+1.06 (6.33%)
The P/E ratio for XERS is -15.68 as of Jul 2, 2025. This represents a increase of 62.99% compared to its 12-month average P/E ratio of -9.62. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Xeris Biopharma Holdings P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Xeris Biopharma Holdings’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Xeris Biopharma Holdings to industry peers.
Xeris Biopharma Holdings P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Xeris Biopharma Holdings’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Xeris Biopharma Holdings to industry peers.
XERS P/E Ratio Insights
See Xeris Biopharma Holdings’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in XERS
Order type
Buy in
Order amount
Est. shares
0 shares
XERS P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $4.66 | -15.45 |
Jun 2, 2025 | $5.05 | -16.74 |
May 1, 2025 | $4.48 | -11.91 |
Apr 1, 2025 | $5.08 | -13.50 |
Mar 3, 2025 | $3.69 | -8.41 |
Feb 3, 2025 | $3.59 | -8.18 |
Jan 2, 2025 | $3.46 | -7.89 |
XERS End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -15.68 | +102.85% |
2024 | -7.73 | +48.08% |
2023 | -5.22 | +301.54% |
2022 | -1.30 | -32.29% |
2021 | -1.92 | -11.11% |
2020 | -2.16 | — |
FAQs About Xeris Biopharma Holdings (XERS) P/E ratio
The latest P/E ratio of XERS is -15.68, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Xeris Biopharma Holdings’s last 12-month average P/E ratio is -9.62, compared to its current P/E ratio of -15.68. This reflects a increase of 62.99%.
Xeris Biopharma Holdings’s current P/E ratio of -15.68 is higher than its last 12-month average P/E of -9.62. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Xeris Biopharma Holdings’s average P/E ratio over the last 3 years is -5.64. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Xeris Biopharma Holdings’s average P/E ratio over the last 5 years is -4.09. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.